Oramed Pharmaceutical Inc. Technology
Oramed is a contemporary pharmaceutical company that is mainly focused into developing new cutting-edge medicinal diabetic drugs that have not been in existence before. Similar to other pharmaceutical companies, technology is a key factor in the success such companies. In an exclusive interview on www.wallst.net with Nadav Kidron, Oramed’s CEO, he was quoted describing Oramed Pharmaceuticals Inc. as “an Israeli company focused on the development of oral delivery solutions based on proprietary technology” (PR Newswire Association LLC, 2007). Kidron’s comment demonstrates the value of technology to Oramed causing the company to patent its technology and product.
Lately Oramed focused on the development of a new diabetic drug called ORMD0801. This product, in a form of a gel capsule, can be consumed orally. ORMD0801 in turn, plays a role in eliminating the need for insulin delivery by the means of self-injecting and constant painful testing of insulin blood levels. In order to accomplish this function, Oramed will need sophisticated technology and certainly top-notch high-tech equipment. Therefore, Oramed has to in an ongoing basis to secure “in-licensing and other means of obtaining additional technologies to complement and/or expand its product portfolio” (The New York Times, 2012).
Oramed’s emerging ORMD0801 delivery is a technology in its-self. It advances the ability of the body to absorb peptides and proteins through the intestinal track wall without creating any changes to the active ingredients of the drug (Oramed, 2009). This was possible by introducing a substitute “drug delivery system” (Oramed Pharmaceuticals Inc., 2010). This delivery system will successfully deliver the drug to ...
... middle of paper ...
...012/03/20/idUS125396+20-Mar-2012+BW20120320
PR Newswire Association LLC. (2007). Exclusive Interview With Oramed Pharmaceuticals Inc. CEO, Nadav Kidron on www.Wallst.Net. PR Newswire. ProQuest Newsstand. http://proquest.umi.com/pqdlink?vinst=PROD&fmt=3&startpage=-1&vname=PQD&RQT=309&did=1256371181&scaling=FULL&vtype=PQD&rqt=309&TS=1333335886&clientId=20655
PR Newswire Association LLC. (2009). Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award. PR Newswire. http://proquest.umi.com.ezproxy.liberty.edu:2048/pqdlink?vinst=PROD&fmt=3&startpage=1&vname=PQD&RQT=309&did=1844533951&scaling=FULL&vtype=PQD&rqt=309&TS=1333049930&clientId=20655
The New York Times. (2012). Business Day. Retrieved from NY Times.com: http://topics.nytimes.com/top/news/business/companies/oramed-pharmaceuticals-inc/index.html
Spikoff, Martin. Controversy Continues to Surround Generic Insulin. 16 April 2008. 9 October 2009 .
17). Dowieko (2015) points out that “methods of administration and routes of administration are important factors that affect the user experience” (p.17). There are thirteen different ways that a compound can be introduced to the body (Kamienski and Keogy (2006), Doweiko, 2015, p. 17). Compounds administered by the “enteral method enter the body by the gastrointestinal tract ”(Brody, 1994, Dowieko ,2015, p. 17). “Compounds administered by the parenteral method of drug administration involves the injection of a compound directly into the body” (Dowieko, 2015,
The capabilities of Abbvie in developing and innovating therapies, nutritional products, medical products and life-changing products to patients needing the most have recognized Abbvie as a top notch pharmaceutical leader. The projects undertaken with the technology and scientific advancements at Abvie demonstrate a greater level of Leadership qualities in administering, delivering and managing such high volume of products, sales, commercial, supply chain management systems etc.
Its products treat the underlying cause of genetically based diseases by delivering corrective genes to the patient’s own bone marrow, providing the potential for a one-time transformative treatment. Genetix's lead clinical product in development is Lenti-D™ for Adrenoleukodystrophy (ALD), also known as Lorenzo's Oil disease. The results of the ongoing ALD trial, based upon work conducted by the National Institute of Health and Medical Research (INSERM), were named to Science magazine's "Scientific Breakthroughs of 2009." In addition to ALD, Genetix is conducting Phase I/II trials with its LentiGlobin™ product in beta-Thalassemia. To date, all patients receiving the full therapy with both products have shown disease arrest. In addition to Genetix’s lead programs, the company’s proprietary stem cell processing, GMP manufacturing and gene therapy vector technologies are applicable to treating other genetic diseases, opening the door to develop more
PharmaCARE is one of the world 's most successful pharmaceutical companies that is enjoying a status as a nurturing, ethical and well-run business that manufactured high-quality healthcare products. Thus, saved millions of inhabits and enhanced the value of life for millions of people. The company provides free and discounted pharmaceuticals to low-income customers on the base of sponsors health care informative programs and scholarships. Two years before, after PharmaCARE 's research identified that one of its peak trading diabetes drugs (AD23) might slow the progression of Alzheimer 's infection. After identifying the weakness, its pharmacists began reformulating that pharmaceutical to maximize the effect. To avoid FDA inspection, PharmaCARE used US law to protect its intellectual property as it established a wholly-owned subsidiary, CompCARE that is set up beside its parent’s headquarters in a suburban agency park.
Main Issue In 2000, Rich Kender, Vice President of Financial Evaluation and Analysis at Merck & Company was discussing the opportunity of investing in licensing, manufacturing and marketing of Davanrik, a drug originally developed to treat depression by LAB Pharmaceuticals. LAB proposed to sell the rights of all the future profits made from the successful launch of Davanrik at the cost of an initial fee, royalty payments and additional payments as the drug completed each stage of the approval process. Merck & Company's organizational goal is to constantly refresh its drug development portfolio and reach as many customers as possible during the patented period. So there was not only the potential of financial gain or quantitative aspect of the offer, but also the qualitative value which will be added by getting better positioning in the risky pharmaceutical industry.
Throughout many generations the success of medicine has been dog-eared throughout history, from penicillin being created through colonized bacteria on an agar plate to chemotherapy being used to combat the ailments of cancer, we as a society rely a great deal on the effectiveness of medicine. Due to this realization one can agree that it is imperative that the medications that are being distributed and placed on the pharmaceutical market are tested and analyzed at all angles and perspectives to ensure they work effectively and successfully resulting in moderate to no side effects. The progressive industry of medicine has greatly increased since the early nineties thanks to the advancement in medical technology making
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
Upon my return from Africa, a new direction opened for me, and I stepped into a career in the pharmaceutical industry, exposing me to several facets and specialties of medicine. Simultaneously,
Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has contributed great discoveries like the first cervical cancer vaccine and great resources like the Merck Manuals which are utilized as a source of information to doctors, scientists and consumers worldwide .
There is an increasing pressure within pharmaceutical markets to reduce prices in line with medical budgets, as well as maintaining patent expirations. Being a global brand means disturbance in the operations when the market fluctuates. There is an internal weakness in the pharmaceutical industry, which includes theft and counterfeiting of drugs, and therefore is a weakness of Johnson & Johnson. While Johnson & Johnson has these specified weaknesses they deal with, there are even more opportunities which gives them an advantage for strengthening their position in the market. They already have the strength of meeting a broader range of customer needs with their products falling under three categories. Expiring patents on brand name drugs lead to an increase in the sales of generic drugs, Johnson & Johnson could capitalize upon this opportunity. With diagnostic markets growing, this positions the company in a good place as well as new medical therapies and findings that align with some of the company’s primary capabilities. Threats the company faces is with product recalls, extreme competition in pharmaceuticals that results usually in the first to enter is generally where success is determined. With technology developments, biotech concepts might possibly move the traditional pharmaceutical methods out of the
This report is a mix of primary research (through surveys on diabetics and interviews with doctors and diabetic specialists) and secondary research (through the research of current and developing technology and treatment. Through this research I aim to raise awareness of new technology and treatment for diabetes which may not be filtering through to the public rapidly enough (perhaps as a result of monopolies held by certa...
We first began our analysis of Novartis by evaluating the company’s strategic direction. Novartis’ mission statement is to care and to cure. They are a company that wants to discover, develop, and successfully market innovative products to prevent and cure disease, to ease suffering, and to enhance the quality of life. Novartis also hopes to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest their money, their time, and their ideas in their company. Like most companies in the industry, Novartis’ vision is to become the best pharmaceutical company through the achievement of sustainable and profitable growth. Novartis has a performance oriented culture and top down leadership style. By having a performance oriented culture the business pushes creativity and free thinking while focusing ...
Pfizer works to deliver, invent and to develop safe and effective ways to prevent or treat some of the world's most challenging diseases. They have invested more than $7 billion annually in research and development, and work with more...
Thomas, Lewis. “The Technology of Medicine”. The McGraw Hill Reader. 8th ed. Ed. Gilbert H. Muller. New York: McGraw Hill, 2003. 581-585.